SCHEMBL16207668

SCHEMBL16207668

C[C@@H](O)[C@@H](CO)NC(=O)CCSSCCNC(=O)CCCC[C@@H]1CCSS1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CAPN1 P07384 2/20 0.45
▸ ACHE P22303 7/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ TARDBP Q13148 2/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ NR1I2 O75469 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ APEX1 P27695 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ PMP22 Q01453 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16207669 1.00 CA12 (0.48) CA12CA9CAPN1ACHEHSD17B10
SCHEMBL16215647 0.88 CA12 (0.44) CA12CA9CAPN1ACHEHSD17B10
SCHEMBL16949986 0.88 KMT2A (0.52) CA12CA9CAPN1ACHEHSD17B10
SCHEMBL16982821 0.88 KMT2A (0.52) CA12CA9CAPN1ACHEHSD17B10
SCHEMBL16207692 0.78 BCHE (0.47) CA12CA9CAPN1ACHEBCHE
SCHEMBL17583803 0.78 BCHE (0.47) CA12CA9CAPN1ACHEBCHE
SCHEMBL17583806 0.78 BCHE (0.47) CA12CA9CAPN1ACHEBCHE
SCHEMBL15124081 0.78 CA12 (0.58) CA12CA9CAPN1ACHEHSD17B10
SCHEMBL15124079 0.76 KMT2A (0.59) CA12CA9CAPN1ACHEHSD17B10
SCHEMBL7840541 0.75 ACHE (0.56) CA12CA9CAPN1ACHEHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160075680-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES FUNDACION IMDEA NANOCIENCIA (ES) 2016-03-17 — — US disclosed
EP-2992002-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES Fundación Imdea Nanociencia (ES) 2016-03-09 — — EP disclosed
WO-2014177533-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES FUNDACIÓN IMDEA NANOCIENCIA (ES) 2014-11-06 — — WO disclosed
WO-2014177533-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES FUNDACIÓN IMDEA NANOCIENCIA (ES) 2014-11-06 — — WO disclosed
EP-2799443-A1 Modified solid support for the synthesis of oligonucleotides Fundación Imdea Nanociencia (ES) 2014-11-05 — — EP disclosed
EP-2799443-A1 Modified solid support for the synthesis of oligonucleotides Fundación Imdea Nanociencia (ES) 2014-11-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160075680-A1 MODIFIED SOLID SUPPORT FOR THE SYNTHESIS OF OLIGONUCLEOTIDES POLR2H, POLRMT, POLR2E CA12 2269/4885CA9 3445/4885CAPN1 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback